Skip to content

Esketamine research published in 2024

Page 2 of 7: studies 21 to 40 of 136, newest first. Back to the esketamine overview

Studies

S-ketamine alleviates depression-like behavior and hippocampal neuroplasticity in the offspring of mice that experience prenatal stress.

Scientific Reports November 6, 2024 Yan Zhang, Chu-Ke Wei, Ping Wang et al. 12 citations

Prenatal stress exerts long-term impact on neurodevelopment in the offspring, with consequences such as increasing the offspring's risk of depression in adolescence and early adulthood. S-ketamine can produce rapid and robust antidepressant effects, but it is not clear yet whether and how S-ketamine alleviates depression in prenatally stressed offspring. The current study incestigated the...

Psychometric properties of the 23-Item Clinician Administered Dissociative States Scale (CADSS) in a psychological trauma population.

Journal of Affective Disorders November 1, 2024 J Douglas Bremner, David Williamson, Viola Vaccarino 5 citations

Dissociative symptoms are both a pathological consequence of exposure to psychological trauma as well as a side effect of N-methyl-d-aspartate (NMDA) receptor antagonist medications; therefore, accurate and valid assessment of these symptoms is important. The psychometric properties of the 23-item Clinician Administered Dissociative States Scale (CADSS) have been characterized in the ketamine...

The effect of a subclinical dose of esketamine on depression and pain after cesarean section: A prospective, randomized, double-blinded controlled trial.

Medicine November 1, 2024 Xiangqian Wan, Ming Li, Xiantao Li et al. 8 citations

The aim of this randomized, double-blind placebo-controlled clinical trial was to study the effects of subclinical doses of esketamine on postpartum depression and pain following elective cesarean sections. This randomized, double-blind placebo-controlled trial included 150 pregnant women undergoing elective cesarean sections. After umbilical cord clamping, participants received either...

DOI: 10.1097/MD.0000000000040295 (opens in new tab) Full text (opens in new tab) Pain management Obstetrics Anesthesia Cesarean section +1

Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies.

The International Journal of Neuropsychopharmacology November 1, 2024 Randall L. Morrison, Jaskaran Singh, Ella Daly et al. 9 citations

While esketamine is effective in treatment-resistant depression (TRD), detailed information about the effect of esketamine on cognition is relatively scarce. This analysis assessed the effect of short-term (3 double-blind [DB] studies: DB1, DB2, and DB4) or long-term maintenance treatment (DB3) with esketamine nasal spray (ESK) compared with a placebo (PBO) combined with active-comparator, on...

DOI: 10.1093/ijnp/pyae046 (opens in new tab) Full text (opens in new tab) Esketamine Cogstate battery test Randomized controlled trials Depression treatment +7

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): commentary, Joks et al.

The British Journal of Psychiatry November 1, 2024 Gero Joks, Steve Su, Jarrad King

Regarding the article, 'Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial', we commend Loo et al for undertaking the Ketamine for Adult Depression Study (KADS). In the interest of ensuring that accurate and balanced information is presented to healthcare...

DOI: 10.1192/bjp.2024.79 (opens in new tab) Full text (opens in new tab) Major depressive disorder Depression/mental health/mental illness Ketamine/esketamine/psychedelics Treatment-resistant depression/trd/refractory depression

Efficacy of esketamine for perinatal depression: a systematic review and meta-analysis.

CNS Spectrums October 31, 2024 Sabrina Wong, Gia Han Le, Angela T H Kwan et al. 10 citations

Postpartum depression (PPD), now referred to as perinatal depression, is a prevalent and debilitating mood disorder that reduces health-related quality of life (HRQoL) and psychosocial functioning. Esketamine, which is efficacious in adults with treatment-resistant depression and individuals with depression and suicidality, is also analgesic in pain management during childbirth labour. Herein,...

DOI: 10.1017/S1092852924000452 (opens in new tab) Full text (opens in new tab) Spravato Mdd prevention Perinatal depression Postpartum depression ppd +4

Ketamine-induced altered states of consciousness: a systematic review of implications for therapeutic outcomes in psychiatric practices.

European Archives of Psychiatry and Clinical Neuroscience October 28, 2024 Kaike Thiê da Costa Gonçalves, Vagner Deuel O de Tavares, Maria Luiza de Morais Barros et al. 5 citations

This systematic review aims to elucidate the nexus between ketamine's psychoactive properties and its efficacy in treating a broad spectrum of psychiatric disorders. We searched three databases and used citation tracking to include 29 studies. Predominantly, mood disorders, including bipolar disorder (BD) and major depressive disorder (MDD) (MDD + BD: + n = 25 studies), a large part of them...

Effect of different doses of esketamine on the median effective concentration of propofol for inhibiting body movement during hysteroscopy.

Scientific Reports October 24, 2024 Ji-Xiang Wan, Si-Si Zeng, Zhi-Qiang Wu et al. 4 citations

The objective of this study is to investigate the effects of various doses of esketamine on the median effective concentration (EC50) of propofol required for inhibiting body movement during hysteroscopy. Additionally, this research aims to explore the pharmacodynamic interactions between esketamine and propofol. Prospective, double-blind, up-down sequential allocation study. Operating room,...

DOI: 10.1038/s41598-024-75902-3 (opens in new tab) Full text (opens in new tab) Anesthetics Ec50 Anesthesia anaesthesia Anaesthetic +4

Improvement in pain by using lidocaine combined with esketamine in elderly patients receiving local anaesthesia for percutaneous kyphoplasty: a randomized controlled study.

BMC Anesthesiology October 23, 2024 Longyuan Zhou, Lei Lv, Ruilan Wu et al. 4 citations

Elderly patients often experience severe pain during percutaneous kyphoplasty under local anaesthesia. The aim of this work was to evaluate the effect of lidocaine combined with esketamine on pain improvement in elderly patients receiving local anaesthesia via percutaneous kyphoplasty. This prospective, randomized comparative trial was conducted on 66 elderly patients, aged 60-80 years, with an...

A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists.

Journal of Affective Disorders October 15, 2024 Angela T H Kwan, Joshua D. Rosenblat, Rodrigo B. Mansur et al. 13 citations

Ketamine and esketamine are increasingly prescribed in the treatment of resistant mood disorders and persons at risk of suicide. Ketamine is a drug of misuse with increasing non-therapeutic use in the general population. Herein, our aim was to determine whether ketamine and/or esketamine are disproportionately associated with reports of substance and/or alcohol misuse. Replicating a similar...

Efficacy of racemic ketamine or esketamine monotherapy for reducing suicidal ideation in uni- or bipolar depression: a systematic review and meta-analysis.

European Archives of Psychiatry and Clinical Neuroscience October 9, 2024 Jiafeng Li, Ling Ma, Huan Sun et al. 5 citations

The current systematic review and meta-analysis examined the effect of racemic ketamine or esketamine on suicidal ideation in individuals with uni- or bipolar depression. We searched the MEDLINE, Embase, Central, PsycINFO, and Web of Science databases to identify randomized controlled trials that examined the effect of racemic ketamine or esketamine monotherapy on suicidal ideation (SI) in...

Ketamine, Esketamine, and Arketamine: Their Mechanisms of Action and Applications in the Treatment of Depression and Alleviation of Depressive Symptoms.

Biomedicines October 9, 2024 Piotr Kawczak, Igor Feszak, Tomasz Bączek 50 citations

Research over the past years has compared the enantiomers (S)-ketamine (esketamine) and (R)-ketamine (arketamine) of the previously known racemic mixture called ketamine (R/S-ketamine). Esketamine has been found to be more potent, offering three times stronger analgesic effects and 1.5 times greater anesthetic efficacy than arketamine. It provides smoother anesthesia with fewer side effects and...

Results of esketamine administration in a Greek population; A case series.

Psychiatriki October 8, 2024 Petros Fotiadis, Eleni Tsalkitzi, Dimos Dimellis et al.

Esketamine is a non-selective, competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor in the brain. Through NMDA receptor antagonism, esketamine causes a transient increase in glutamate release, leading to increases in neurotrophic signaling and restoration of synaptic function in brain regions involved in mood regulation and emotional behavior. Several randomized clinical trials...

DOI: 10.22365/jpsych.2024.006 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression Fast-acting antidepressant Mood disorders Therapeutic intervention +5

Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting.

The Journal of Clinical Psychiatry October 2, 2024 Mia C Santucci, Mina Ansari, Sina Nikayin et al. 12 citations

Background: Bipolar disorder represents a significant source of morbidity and elevated mortality risk. Ketamine has emerged as a powerful antidepressant; however, there have been few trials of ketamine in bipolar depression and no trials with esketamine in bipolar depression, and few data exist from real-world settings. Here, we report outcomes from a cohort of patients with bipolar depression...

DOI: 10.4088/JCP.24m15376 (opens in new tab) Full text (opens in new tab) Ketamine therapy Bipolar disorder Depression treatment Clinical trials +1

Ketamine and Esketamine Use for Mood Disorders with Psychosis: A Systematic Review of Dissociative and Psychotic Symptoms

CNS Spectrums October 1, 2024 Renzo Costa, Ayyub Imtiaz, Jacob Adelman et al.

Introduction Ketamine is used off-label for suicidality and mood disorders, whereas esketamine is FDA-approved for treatment-resistant depression in adults. However, many of these studies have excluded patients with a history of or currently presenting with psychosis. A significant number of patients who have primary mood disorders with psychotic features need novel psychopharmacological...

Effect of Esketamine on Postoperative Delirium in Patients Undergoing Cardiac Valve Replacement with Cardiopulmonary Bypass: A Randomized Controlled Trial.

Anesthesia & Analgesia October 1, 2024 Xinglong Xiong, Yi Shao, Dongxu Chen et al. 41 citations

The aim of this study was to investigate the effects of esketamine on the risk of postoperative delirium (POD) in adults undergoing on-pump cardiac valve surgery. In this randomized, triple-blind, controlled trial, 116 adult patients with an American Society of Anesthesiologists (ASA) grade Ⅱ or Ⅲ and a New York Heart Association (NYHA) grade Ⅱ or Ⅲ who underwent cardiac valve surgery with...

IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression.

Psychiatry Research October 1, 2024 Gilmar Gutierrez, Jennifer Swainson, Nisha Ravindran et al. 17 citations

Intravenous (IV) ketamine and intranasal (IN) esketamine are novel therapies to manage treatment resistant depression within major depressive disorder (MDD-TRD). This is a multi-site observational study aiming to assess the real-world effectiveness and tolerability of these novel therapies in the management of MDD-TRD. 53 patients were referred to receive IV ketamine (n = 26, 69.23 % female,...

Esketamine mitigates mechanical ventilation-induced lung injury in chronic obstructive pulmonary disease rats via inhibition of the MAPK/NF-κB signaling pathway and reduction of oxidative stress.

International Immunopharmacology September 30, 2024 San-Ying Cai, Ang Liu, Wen-Xi Xie et al. 13 citations

To investigate esketamine's impact on inflammation and oxidative stress in ventilated chronic obstructive pulmonary disease (COPD) rats, examining its regulatory mechanisms. Rats were divided into four groups: control group (Con), COPD model group (M), COPD model with saline treatment group (M+S), and COPD model with esketamine treatment group (M+K), with 12 rats in each group. After two...

DOI: 10.1016/j.intimp.2024.112725 (opens in new tab) Full text (opens in new tab) Esketamine Inflammation Mechanical ventilation Oxidative stress +5

Inflammatory cytokines, cortisol, and anhedonia in patients with treatment-resistant depression after consecutive infusions of low-dose esketamine.

European Archives of Psychiatry and Clinical Neuroscience September 28, 2024 Yue Wang, Qiongyao Yang, Chuanchuan Chen et al. 10 citations

Anhedonia, defined as a significant loss of interest or pleasure, is one of the core symptoms of treatment- resistant depression (TRD) and is often associated with poor prognosis. This article primarily investigates the changes in anhedonia symptoms, inflammatory markers, and cortisol levels in TRD patients after low-dose esketamine treatments. A total of sixty patients with TRD were enrolled...

Efficacy and safety of esketamine hydrochloride adjunct to sufentanil in non-surgical patients under mechanical ventilation in the ICU (SENSATION trial): protocol for a multicentre, single-blind, randomised controlled trial.

BMJ Open September 25, 2024 Yi Long, Donghuang Hong, Haibin Ni et al. 1 citation

Pain is common in patients receiving mechanical ventilation in the intensive care unit (ICU). Intravenous opioids are recommended as first-line therapy for pain management; however, opioids have adverse side effects. Based on low-quality evidence, low-dose ketamine is therefore recommended as an opioid adjunct to reduce opioid consumption. Esketamine is an alternative to ketamine with greater...

DOI: 10.1136/bmjopen-2024-084469 (opens in new tab) Full text (opens in new tab) Pain management Randomized controlled trial Critical care medicine Esketamine therapy +2